Drug Profile
Research programme: transdermal protein therapeutics - CSL/Avecho Biotechnology
Alternative Names: CSL activesLatest Information Update: 29 Dec 2020
Price :
$50
*
At a glance
- Originator CSL; Phosphagenics
- Developer Avecho Biotechnology; CSL
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Australia (Transdermal)
- 20 Apr 2012 Early research is ongoing in Australia
- 19 Jun 2009 Early research in Undefined indication in Australia (Transdermal)